Effects of omega-3 polyunsaturated fatty acids supplements on psychopathology and metabolic parameters in schizophrenia: A meta-analysis of randomized controlled trials
Effects of omega-3 polyunsaturated fatty acids supplements on psychopathology and metabolic parameters in schizophrenia: A meta-analysis of randomized controlled trials
复制标题
DOI：
10.1177/0269881120981392
复制
发表时间：
2021-03-01
影响因子：
4.1
通讯作者：
Lu, Mong-Liang
中科院分区：
文献类型：
--
作者：
Goh, Kah K.;Chen, Cynthia Yi-An;Lu, Mong-Liang
背景：几种单药治疗和强化治疗策略已被引入以改善精神分裂症的治疗。ω-3多不饱和脂肪酸对精神障碍患者的益处越来越被认可。然而，它在精神分裂症治疗中的作用引起了复杂的考虑，对此几乎没有达成共识。本研究的目的是综合随机对照试验的结果，进行了确定的有效性和安全性的omega-3多不饱和脂肪酸在精神分裂症patients.Methods：MEDLINE，Embase，科克伦，Scopus，和Web of Science数据库检索相关文献。主要结果是精神病理学的变化和次要结果是代谢参数和安全性的变化profiles.Results：20双盲随机对照试验，1494例患者。Omega-3多不饱和脂肪酸的增加与精神分裂症患者的精神病理学显着改善相关，特别是一般精神病理学和阳性症状，但与阴性症状无关。患有严重疾病并接受含有二十碳五烯酸的ω-3多不饱和脂肪酸>1 g/d的患者表现出显著改善。还证明了omega-3多不饱和脂肪酸补充剂对血清甘油三酯的有利影响。Omega-3多不饱和脂肪酸是耐受性良好，安全的精神分裂症患者。结论：这些研究结果初步支持使用的omega-3多不饱和脂肪酸作为一种潜在的增强战略，在精神分裂症。在更大的样本中进行进一步的研究是必要的，以澄清最佳剂量和正确比例的ω-3多不饱和脂肪酸管理，以及阐明潜在的机制。
Background:Several monotherapy and augmentation strategies have been introduced to improve the treatment of schizophrenia. The benefits of omega-3 polyunsaturated fatty acids in patients with mental disorders is becoming increasingly acknowledged. However, its role in the treatment of schizophrenia raises complex considerations about which there has been little consensus. The aim of this study was to synthesize the findings of randomized controlled trials that were conducted to determine the efficacy and safety of omega-3 polyunsaturated fatty acids in patients with schizophrenia.Methods:The MEDLINE, Embase, Cochrane, Scopus, and Web of Science databases were searched for relevant literature. The primary outcome was changes in psychopathology and the secondary outcomes were changes in metabolic parameters and safety profiles.Results:Twenty double-blind randomized controlled trials in 1494 patients were included. Omega-3 polyunsaturated fatty acids augmentation was associated with significantly improved psychopathology in patients with schizophrenia, particularly general psychopathology and positive symptoms but not negative symptoms. Patients who were severely ill and received omega-3 polyunsaturated fatty acids containing eicosapentaenoic acid >1 g/d showed significant improvement. A favorable effect of omega-3 polyunsaturated fatty acids supplements on serum triglycerides was also demonstrated. Omega-3 polyunsaturated fatty acids are well-tolerated and safe in patients with schizophrenia.Conclusions:These findings tentatively support the use of omega-3 polyunsaturated fatty acids as a potential augmentation strategy in schizophrenia. Further research in larger samples is warranted to clarify the optimal dosage and the correct proportions of omega-3 polyunsaturated fatty acids to administer, together with elucidation of the underlying mechanisms.